Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04927247 · ClinicalTrials.gov registry record · Phase 3
A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 72
- Enrollment target
NCT04927247 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 72 participants.
The verdict
NCT04927247, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 72 participants
- Enrollment target
Study Summary
This Phase 3 study will assess the safety and efficacy of a single dose of inclacumab, a P-selectin inhibitor, for a vaso-occlusive crisis (VOC) after an index VOC in participants with sickle cell disease (SCD). Participants will be randomized to receive either inclacumab or placebo.
Interventions
- DRUG Placebo
- DRUG Inclacumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2021-12-09 |
| Est. Completion | 2023-11-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04927247
The ClinicalTrials.gov registry entry for NCT04927247 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04927247 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04927247 about?
NCT04927247 is a clinical study titled "A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises". This Phase 3 study will assess the safety and efficacy of a single dose of inclacumab, a P-selectin inhibitor, for a vaso-occlusive crisis (VOC) after an index VOC in participants with sickle cell disease (SCD). Participants will be randomized to receive either inclacumab or placebo.
What is the current status of trial NCT04927247?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 72 participants. The study started on 2021-12-09. Estimated completion is 2023-11-24.
What interventions are being tested in trial NCT04927247?
The interventions under investigation include: Placebo (DRUG), Inclacumab (DRUG).
Who is sponsoring clinical trial NCT04927247?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.